Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Blood (2012) 120 (21): 3572.

https://doi.org/10.1182/blood.V120.21.3572.3572

Published: 2012

Journal Articles

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

Blood (2012) 120 (21): 677.

https://doi.org/10.1182/blood.V120.21.677.677

Published: 2012

Journal Articles

The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Alfonso Quintas-Cardama, MD, Elias J. Jabbour, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 72.

https://doi.org/10.1182/blood.V120.21.72.72

Published: 2012

Journal Articles

Proteomic Profiling of Smad Proteins Expression in AML: Pan Expression with High Phosphorylation Is Prognostically Adverse

Young Kwang Chae, MD, MPH, Nianxiang Zhang, Yihua Qiu, Tapan M. Kadia, M.D., Alessandra Ferrajoli, M.D., Kevin R. Coombes, PhD, Steven M. Kornblau, MD, PhD

Blood (2012) 120 (21): 891.

https://doi.org/10.1182/blood.V120.21.891.891

Published: 2012

Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD

Blood (2012) 120 (21): 3625.

https://doi.org/10.1182/blood.V120.21.3625.3625

Published: 2012

Journal Articles

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Koichi Takahashi, MD, Naveen Pemmaraju, M.D., Miloslav Beran, Alfonso Quintás-Cardama, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, PhD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Elias J. Jabbour, MD, Naval Daver, MD, Zeev Estrov, MD, PhD, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3797.

https://doi.org/10.1182/blood.V120.21.3797.3797

Published: 2012

Journal Articles

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Aziz Nazha, Hagop M. Kantarjian, MD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Stefan Faderl, MD, Zeev Estrov, MD, PhD, Elias Jabbour, Alfonso Quintas-Cardama, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3587.

https://doi.org/10.1182/blood.V120.21.3587.3587

Published: 2012

Journal Articles

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Koichi Takahashi, MD, Elias J. Jabbour, MD, Xuemei Wang, MS, Hady Ghanem, MD, Naveen Pemmaraju, M.D., Farhad Ravandi, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Zeev Estrov, MD, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3802.

https://doi.org/10.1182/blood.V120.21.3802.3802

Published: 2012

Journal Articles

A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily × 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, PhD, Gautam Borthakur, M.D., Susan M. O'Brien, MD, Tapan M. Kadia, M.D., Marina Konopleva, MD, PhD, Naval Daver, MD, Mark Brandt, BS, Heather Schroeder, RN, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 3851.

https://doi.org/10.1182/blood.V120.21.3851.3851

Published: 2012

Journal Articles

Outcome of Patients (pts) with Acute Myeloid Leukemia (AML) Evolving From Myelodysplastic Syndromes (MDS) Post Hypomethyling Agents (HMA) Failure

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Guillermo Garcia Manero, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Koichi Takahashi, MD, Susan M. O'Brien, MD, Sherry A. Pierce, RN, BS, Tapan M. Kadia, M.D., Elias J. Jabbour, MD

Blood (2012) 120 (21): 3600.

https://doi.org/10.1182/blood.V120.21.3600.3600

Published: 2012

Journal Articles

Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms

Lakshmikanth Katragadda, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Alessandra Ferrajoli, M.D., Elias J. Jabbour, MD, Alfonso Quintas-Cardama, MD, Marina Konopleva, M.D., Ph.D., Manoj Maniar, PhD, Francois Wilhelm, MD, PhD., Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3606.

https://doi.org/10.1182/blood.V120.21.3606.3606

Published: 2012

Journal Articles

Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen

Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Yin Cameron, MD, PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Hady Ghanem, MD, Tapan M. Kadia, M.D., Stefan Faderl, MD, Susan O'Brien, M.D., Michael S Mathisen, PharmD, Mark Brandt, BS, Naveen Pemmaraju, M.D., Deborah A. Thomas, MD, Joyce Bass, RN, Gautam Borthakur

Blood (2012) 120 (21): 3609.

https://doi.org/10.1182/blood.V120.21.3609.3609

Published: 2012

Journal Articles

Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients

Michael Andreeff, MD, PhD, Zhihong Zeng, PhD, Mary A Kelly, RN, Rui-yu Wang, MD, PhD, Teresa McQueen, BS, Seshagiri Duvvuri, Gul Nowshad, Gautam Borthakur, MD, Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Elias Jabbour, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD, PhD

Blood (2012) 120 (21): 142.

https://doi.org/10.1182/blood.V120.21.142.142

Published: 2012

Journal Articles

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2012) 120 (21): 43.

https://doi.org/10.1182/blood.V120.21.43.43

Published: 2012

Journal Articles

Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy

Aziz Nazha, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Sherry A. Pierce, RN, BS, Naval G. Daver, MD, Naveen Pemmaraju, M.D., Farhad Ravandi, MD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Alfonso Quintas-Cardama, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 4928.

https://doi.org/10.1182/blood.V120.21.4928.4928

Published: 2012

Journal Articles

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D., Stefan Faderl, MD, Sara E Dellasala, RN, Susan M. O'Brien, MD, Jan A. Burger, MD, PhD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Alfonso Quintás-Cardama, MD, Mark Brandt, BS, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 4939.

https://doi.org/10.1182/blood.V120.21.4939.4939

Published: 2012

Journal Articles

Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

Naveen Pemmaraju, M.D., Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Tapan M. Kadia, M.D., Jorge E. Cortes, MD, Gautam Borthakur, M.D., Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Farhad Ravandi, MD, Alfonso Quintas-Cardama, MD, Elias J. Jabbour, MD, Charles Asa Koller, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Elizabeth M Burton, Srdan Verstovsek, MD, PhD

Blood (2012) 120 (21): 3617.

https://doi.org/10.1182/blood.V120.21.3617.3617

Published: 2012

Journal Articles

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Naval Daver, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Marina Konopleva, MD, PhD, Jan A. Burger, MD, PhD, Susan O'Brien, M.D., Alessandra Ferrajoli, M.D., Srdan Verstovsek, MD, PhD, Tapan M. Kadia, M.D., Elias J. Jabbour, MD, Stefan Faderl, MD, Maria Diaz-Pines-Mateo, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Gautam Borthakur, M.D.

Blood (2012) 120 (21): 3619.

https://doi.org/10.1182/blood.V120.21.3619.3619

Published: 2012

Journal Articles

Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy

William G. Wierda, MD, PhD, Kumudha Balakrishnan, Alessandra Ferrajoli, M.D., Susan O'Brien, M.D., Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Jorge E. Cortes, MD, Francesco Paolo Tambaro, MD, PhD, Annette Jalayer, RN, Susan Lerner, MS, Michael J. Keating, MD, Varsha V. Gandhi, Ph.D.

Blood (2012) 120 (21): 437.

https://doi.org/10.1182/blood.V120.21.437.437

Published: 2012

Journal Articles

Cytogenetic and Molecular Characterization of Genitourinary Extramedullary Disease in Acute Myeloid Leukemia

Kathy M. Tran, Hagop M. Kantarjian, MD, Syed M. Kazmi, MD, Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, Maro Ohanian, DO, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Farhad Ravandi, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 4326.

https://doi.org/10.1182/blood.V120.21.4326.4326

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP)

Proteomic Profiling of Smad Proteins Expression in AML: Pan Expression with High Phosphorylation Is Prognostically Adverse

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily × 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

Outcome of Patients (pts) with Acute Myeloid Leukemia (AML) Evolving From Myelodysplastic Syndromes (MDS) Post Hypomethyling Agents (HMA) Failure

Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms

Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen

Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy

Cytogenetic and Molecular Characterization of Genitourinary Extramedullary Disease in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only